XJSE
APN
Market cap4.23bUSD
Sep 17, Last price
15,579.00ZAR
1D
-0.36%
1Q
1.00%
Jan 2017
-45.06%
Name
Aspen Pharmacare Holdings Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aspen Pharmacare Holdings Limited is a global pharmaceutical entity that develops, manufactures, and distributes a wide array of specialized and branded medicinal products. The company operates through two primary segments: Commercial Pharmaceuticals and Manufacturing. Its diverse product portfolio encompasses essential anesthetic agents, such as general anesthetics, muscle relaxants, and topical preparations. Aspen also provides a comprehensive suite of thrombosis treatments, including various injectable anticoagulants like low molecular weight heparins, Xa inhibitors, and other heparin derivatives. Beyond these, the firm markets numerous regional consumer, prescription, and over-the-counter brands, such as Circadin for sleep, Foxair for respiratory ailments, Maltofer as an iron supplement, Mybulen for pain management, and Zyloric for gout. Additionally, Aspen produces active pharmaceutical ingredients and finished dose form products for other companies. Established in 1850, the company's headquarters are located in Durban, South Africa.
Related entities
Subsidiaries (14)
Aspen Finance (PTY) Limited
Aspen Global Incorporated
Aspen Healthcare FZ-LLC
Aspen Mexico S De RL De CV
Aspen Oss B.V.
Aspen Pharma Ireland Limited
Aspen Pharma Schweiz GmbH
Aspen Pharmacare Canada Inc.
Aspen Pharmacare UK Limited
Aspen Polska spolka z ograniczona odpowiedzialnoscia
ASPEN TREASURY IRELAND LIMITED
Aspen Treasury SA (Pty) Ltd
Pharmacare
Aspen Europe GMBH
Key people
Stephen Bradley Saad
Group Chief Executive, Executive Director · since 2014
Sean Capazorio
Group Finance Officer · since 1999
Samer Kassem
Chief Executive Officer, Aspen Global Incorporated CEO · since 2008
Stavros Nicolaou
Group Senior Executive Strategic Trade · since 1999
Riaan Verster
Company Secretary and Group Governance Officer · since 2013
Christopher Nattle Mortimer
Non-Executive Director · since 1999
Non-Executive Director · since 2015
Ben Kruger
Lead Independent Non-Executive Director · since 2019
Headquarters & legal address
Building 8
Healthcare Park
Woodlands Drive
Johannesburg, GP 2052
ZA
Healthcare Park
Woodlands Drive
Johannesburg, GP 2052
ZA
Valuation
Title ZAR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||